AstraZeneca PLC (NASDAQ:AZN) Given Consensus Rating of “Buy” by Brokerages

Shares of AstraZeneca PLC (NASDAQ:AZNGet Rating) have received a consensus recommendation of “Buy” from the fourteen analysts that are covering the company, MarketBeat reports. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $7,223.13.

AZN has been the subject of a number of research reports. Stifel Nicolaus initiated coverage on shares of AstraZeneca in a research report on Monday, February 28th. They set a “buy” rating for the company. JPMorgan Chase & Co. increased their price objective on shares of AstraZeneca from £100 ($127.45) to £120 ($152.94) in a research report on Thursday, April 7th. SVB Leerink increased their price objective on shares of AstraZeneca from $65.00 to $70.00 and gave the company an “outperform” rating in a research report on Thursday, February 24th. DZ Bank upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Friday, February 11th. Finally, Barclays increased their price objective on shares of AstraZeneca from £115 ($146.57) to £120 ($152.94) in a research report on Thursday, April 14th.

AZN opened at $65.06 on Wednesday. The firm has a market cap of $201.61 billion, a P/E ratio of 464.75, a PEG ratio of 1.27 and a beta of 0.48. AstraZeneca has a 1-year low of $50.66 and a 1-year high of $71.70. The company has a 50 day simple moving average of $64.15 and a two-hundred day simple moving average of $60.46. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.16 and a quick ratio of 0.76.

AstraZeneca (NASDAQ:AZNGet Rating) last issued its earnings results on Thursday, February 10th. The company reported $0.84 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.77 by $0.07. AstraZeneca had a net margin of 0.30% and a return on equity of 27.48%. The firm had revenue of $11.50 billion during the quarter, compared to analyst estimates of $11.06 billion. During the same quarter in the prior year, the business earned $0.54 earnings per share. AstraZeneca’s revenue for the quarter was up 55.2% on a year-over-year basis. Equities analysts anticipate that AstraZeneca will post 3.32 earnings per share for the current year.

The firm also recently announced a semi-annual dividend, which was paid on Monday, March 28th. Shareholders of record on Friday, February 25th were given a dividend of $0.985 per share. This is an increase from AstraZeneca’s previous semi-annual dividend of $0.45. The ex-dividend date of this dividend was Thursday, February 24th. This represents a yield of 2.4%. AstraZeneca’s dividend payout ratio (DPR) is 1,378.67%.

Institutional investors have recently modified their holdings of the company. RB Capital Management LLC lifted its holdings in shares of AstraZeneca by 1.8% during the 1st quarter. RB Capital Management LLC now owns 8,381 shares of the company’s stock valued at $556,000 after purchasing an additional 151 shares during the last quarter. Pinnacle Bancorp Inc. increased its position in shares of AstraZeneca by 13.4% in the 1st quarter. Pinnacle Bancorp Inc. now owns 1,317 shares of the company’s stock valued at $87,000 after acquiring an additional 156 shares during the period. Kingsview Wealth Management LLC increased its position in shares of AstraZeneca by 2.5% in the 3rd quarter. Kingsview Wealth Management LLC now owns 7,168 shares of the company’s stock valued at $431,000 after acquiring an additional 176 shares during the period. BerganKDV Wealth Management LLC increased its position in shares of AstraZeneca by 27.4% in the 3rd quarter. BerganKDV Wealth Management LLC now owns 842 shares of the company’s stock valued at $51,000 after acquiring an additional 181 shares during the period. Finally, Regal Investment Advisors LLC increased its position in shares of AstraZeneca by 4.8% in the 4th quarter. Regal Investment Advisors LLC now owns 4,038 shares of the company’s stock valued at $235,000 after acquiring an additional 185 shares during the period. 20.54% of the stock is currently owned by hedge funds and other institutional investors.

About AstraZeneca (Get Rating)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

See Also

Analyst Recommendations for AstraZeneca (NASDAQ:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.